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Abstract
The direct intracellular delivery of proteins has, until recently, been difficult to achieve, due
primarily to the bioavailability barrier of the plasma membrane. During the past 15 years, a va-
riety of peptides called protein transduction domains (PTDs) or cell penetrating peptides (CPPs),
have been characterized for their ability to translocate into live cells. The most commonly stud-
ied are homeodomain transcription factors such as Antennapedia, the herpes simplex virus (HSV)
type 1 protein VP22, and the human immunodeficiency virus (HIV-1) transactivator TAT protein.
Recently, polyarginine exhibits even greater efficiency in terms of delivery of several peptides
and proteins. Numerous examples of biologically active full-length proteins and peptides have
been delivered to cells and tissues, both in vitro and in vivo. These studies offer new avenues
for treatment of several diseases. The main mechanism of protein transduction is an electrostatic
interaction with the plasma membrane, penetration into cells by macropinocytosis, and a release to
cytoplasm and nuclei by retrograde transport. Moreover, the intercellular transfer of endogenous
transcription factors, such as TAT and homeoproteins, seems to point to an original and important
mode of signal transduction. The protein transduction systems have opened up several possibili-
ties, not only for the development of new peptide/protein drugs but also for consideration of their
physiological and developmental implications.
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he plasma membrane consists of a lipid bilayer 
into which proteins and glycoproteins are inserted. 
In general,  the hydrophobic nature of these lipids 
makes it impossible for the vast majority of peptides 
and proteins to cross the membrane.  A signiﬁ cant 
exception to this rule have recently been pointed out, 
with the identiﬁ cation of several protein transduction 
domains (PTDs),  also known as cell-penetrating pep-
tides (CPPs),  that are capable of transducing cargo 
across the membrane,  allowing proteins to accumu-
late within the cell.  The most commonly studied are 
homeodomain transcription factors such as 
Antennapedia (Antp) [1ﾝ6],  the herpes simplex virus 
(HSV) type 1 protein VP22 [7],  and the human 
immunodeﬁ ciency virus (HIV-1) transactivator TAT 
protein [8ﾝ13].  Recently,  poly-arginine (polyR) and 
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poly-lysine have been shown to exhibit even greater 
eﬃ  ciency in terms of delivery of several peptides and 
proteins [14ﾝ18].  Signiﬁ cantly,  when synthesized as 
recombinant fusion proteins or covalently cross-
linked to full-length proteins,  these PTDs are capa-
ble of delivering biologically active proteins.  These 
PTD fusion proteins are found in both the cytoplasm 
and the nucleus.  Studies by our group,  along with 
those by others,  have demonstrated how these pro-
tein transduction systems have opened up several 
possibilities for the development of new peptide/pro-
tein drugs [1,  12,  14,  15,  19,  20].  Here,  we 
review some of the most recent advances in this rap-
idly expanding area of research.
Intracellular Delivery of PTD-Conjugated 
Macromolecules
　　The most impressive aspect of PTD-mediated 
delivery and its therapeutic potential is its size inde-
pendence.  The ability of PTDs to deliver cargo into 
cells is not limited only to proteins or peptides. 
Several PTDs have been shown to mediate the eﬃ  -
cient intracellular accumulation of non-organic mole-
cules.  The broad utility of protein transduction tech-
nology is illustrated schematically in Fig. 1.
　　Protein and peptide delivery.　 Proteins 
have been evolutionarily selected to perform speciﬁ c 
functions.  Thus,  the ability to deliver a wide variety 
of full-length,  functional proteins has tremendous 
potential as a biological tool for studying cellular 
processes as well as for developing novel and poten-
tially very speciﬁ c therapeutic agents.  To date,  a 
growing number of transducible proteins covering a 
wide range of sizes and functional classes have been 
successfully used to study intracellular mechanisms. 
These include PDX-1 [1ﾝ3],  BETA2/NeuroD [19], 
Ngn3 [20],  enhanced green ﬂ uorescent protein 
(EGFP) [1,  19],  Cre recombinase [9,  10],  and p53 
[21].  PTDs have been shown to deliver proteins in 
excess of 100 KDa into cultured cells and most,  if 
not all,  cells in mammalian model systems [8].
　　Peptides can be used in a vast range of applica-
tions in pharmaceutical research.  By linking peptide 
sequences to PTDs,  previously non-cell-penetrating 
peptides have been introduced into cells,  thereby 
altering existing protein-protein or protein-oligonu-
cleotide interactions.  Several peptides have been 
fused to PTDs,  thus enabling their entry into the 
cytoplasm.  The introduced peptides inhibit protein 
binding or protein complex formation [11,  12,  14ﾝ
16].  Subsequently,  several reports have described 
the delivery of peptides and proteins in vivo [12, 
14].  Moreover,  Barka T et al.  recently showed the 
advantages and versatility of protein transduction 
over viral transgene delivery [22,  23].  Their stud-
ies using retroviral vectors expressing ｹ-galactosi-
dase [22] were compared with results from the injec-
tion of TAT-ｹ-galactosidase fusion protein in vivo 
[23].  Injection of TAT-ｹ-galactosidase by retro-
grade duct injection resulted in transduction into 100
ｵ of the rat salivary gland cells in a concentration-
dependent manner,  whereas viral delivery could only 
achieve 30ﾝ50ｵ eﬃ  ciency.
　　Delivery of antisense oligonucleotides.
The use of antisense techniques as a pharmaceutical 
tool is interesting because this technology potentially 
has the ability to downregulate the expression of vir-
tually any desired gene.  Antisense techniques are 
based on sequence-speciﬁ c oligonucleotide analogs 
that,  after introduction to the cytosol,  can hybridize 
with complementary mRNA strands.  This hybridiza-
tion causes translational arrest or recruitment of 
RNaseH,  thereby altering the gene expression in the 
cell [24].  The development of antisense therapy has 
focused mainly on improving methods for oligonucle-
otide delivery into cells.  Although the cellular 
uptake of naked oligonucleotides is poor,  it is signiﬁ -
cantly increased by coupling the oligonucleotide to a 
transporter peptide,  leading to decreased expression 
of the gene product of the targeted gene.  Morris et 
al.  describe a potent new strategy for oligonucleotide 
delivery based on the use of a short peptide vector, 
termed MPG,  which contains a hydrophobic domain, 
derived from the fusion sequence of HIV gp41,  and a 
hydrophilic domain,  derived from the nuclear local-
ization sequence of SV40 T-antigen [25].  Tung et al. 
reviews the preparation and applications of PTD-
oligonucleotide conjugates [26].  These strategy of 
oligonucleotide delivery into cultured cells based on 
a peptide vector oﬀ ers several advantages including 
eﬃ  ciency,  stability and absence of cytotoxicity,  when 
compared to other commonly used approaches of 
delivery.  The interaction with PTD strongly 
increases both the stability of the oligonucleotide to 
the nuclease and the crossing of the plasma mem-
2 Acta Med.  Okayama　Vol.  60,  No.  1Noguchi et al.
2
Acta Medica Okayama, Vol. 60 [2006], Iss. 1, Art. 1
http://escholarship.lib.okayama-u.ac.jp/amo/vol60/iss1/1














Fig. 1　　Utility of protein transduction technology.  A wide variety of cargo has been covalently linked to PTDs.  Currently,  most 
molecules can be transduced into cells when linked to a PTD.
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brane.
　　The rapid degradation of natural oligonucle-
otides inside the cell prohibits their use in antisense 
technology ; however,  many oligonucleotide analogs 
have been used in antisense techniques,  with varying 
results.  Astriab-Fisher et al.  showed that PTD-
phosphorothionate oligonucleotide conjugate was 
internalized into cells under serum-replete conditions 
and inhibited expression of the target molecule [27]. 
PTD-PNA could also inhibit the expression (see 
‘Delivery of peptide nucleic acids (PNA)’ section).  The 
development of modiﬁ ed oligonucleotides is con-
stantly progressing [24].  Increased stability, 
enhanced RNA binding aﬃ  nity and lower toxicity are 
just some of the aspects to be considered when choos-
ing a suitable oligonucleotide.
　　Delivery of peptide nucleic acids (PNAs).
PNAs form stable complexes with DNA and RNA, 
have low toxicity and,  unlike naturally occurring oli-
gonucleotides,  are not sensitive to nucleases.  These 
features make them an ideal tool for antisense ther-
apy.  As is the case for the majority of large mole-
cules,  the cellular uptake of these oligonucleotides is 
poor,  but coupling to PTDs increases their uptake 
and thus their applicability as tools for the highly 
speciﬁ c downregulation of desired gene products.  In 
many cases the PTD-PNA construct is not synthe-
sized as a continuous chain because synthesis of a 
continuous chain could interfere with the internaliza-
tion of the construct and the PNA-mRNA interaction. 
Therefore,  the method most frequently employed is 
coupling of the PNA to the peptide via a disulﬁ de 
bond [28,  29].  The disulﬁ de bond has no signiﬁ cant 
eﬀ ect on internalization and,  once inside the cell, 
the conditions of the intracellular environment cause 
the reduction of the disulﬁ de bond,  thereby releasing 
PNAs,  which are then free to interact with the 
desired target [30].  Moreover,  PTD-PNA has been 
shown to enhance the transfection eﬃ  cacy of plas-
mids [31].  In combination with the transfection 
agent polyethyleneimine (PEI),  the eﬃ  cacy of plas-
mid transfection was improved up to eightfold (see 
‘Plasmid delivery’ section).
　　siRNA delivery.　 The recent discovery of 
the RNA interference pathway in a wide variety of 
eukaryotic organisms has provided a novel means of 
characterizing gene function in mammalian cells. 
Short,  interfering RNAs (siRNAs) have considerable 
potential as a powerful tool in molecular biology 
research and in the future as pharmaceutical drugs. 
However,  the major drawback with the use of 
siRNA,  as with most oligonucleotide-based drugs,  is 
the low yield of cellular uptake.  By contrast,  the use 
of a mixture of PTD and siRNA directed towards 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
mRNA increased the cellular uptake of the siRNA 
several fold compared with naked siRNA,  and the 
targeted mRNA was downregulated.  PTD and 
siRNA are not covalently linked,  but form a complex 
through electrostatic interactions [32].  The peptide 
carrier constitutes an excellent tool for the delivery 
of siRNA into cells.
　　Delivery of iron nanoparticles.　 Weisseled-
er’s group [33ﾝ35] recently delivered into cells 
41-nm biocompatible,  dextran-coated superparamag-
netic iron oxide nanoparticles conjugated to TAT-
PTD.  Derivatized particles were internalized into 
lymphocytes over 100-fold more eﬃ  ciently than non-
modiﬁ ed particles.  These particles were also inter-
nalized into both hematopoietic and neural progenitor 
cells at levels up to 10ﾝ30 pg per cell.  Moreover, 
the iron incorporation did not aﬀ ect cell viability, 
diﬀ erentiation,  or proliferation of CD34＋ human 
stem cells.  Following intravenous injection into 
immunodeﬁ cient mice,  4ｵ of magnetically CD34＋ 
cells homed to bone marrow per gram of tissue,  and 
single cells could be detected by magnetic resonance 
(MR) imaging in tissue samples.  The method has 
potential applications for in vivo tracking of magneti-
cally labeled cells by MR imaging and for recovering 
intracellularly labeled cells from organs.
　　Liposome delivery.　 The therapeutic deliv-
ery of polar compounds is often ineﬃ  cient owing to 
the diﬃ  culty of crossing the lipid membrane of cells. 
As a consequence,  delivery of these compounds 
within liposomal carriers has been the focus of 
increasing attention,  but has been hampered by ineﬃ  -
cient cellular uptake and consequent degradation 
through the endocytic pathway.  Recently,  Torchilin 
et al.  [36] demonstrated that relatively large drug 
carriers,  such as 200-nm liposomes,  can be delivered 
into cells by a TAT peptide attached to the liposome 
surface.  Incubation of TAT liposomes with several 
cells results in intracellular localization of certain 
liposomes.  Confocal analysis showed that the lipo-
somes remained intracellularly intact 1 h after trans-
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Fig. 2　　Mechanism of protein transduction.  The primary mechanism of protein transduction is an electrostatic interaction with the 
plasma membrane,  penetration into cells by macropinocytosis,  and release to the cytoplasm and nuclei by retrograde transport.
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duction.  The approach may have important implica-
tions for drug delivery directly into the cell cyto-
plasm.
　　Plasmid delivery.　 Although viral methods 
have several advantages,  they also have many draw-
backs such as the immunological response provoked 
by exposure to viral infection.  Other currently 
employed standard methods,  including the application 
of polycationic agents,  electroporation and microin-
jection,  are ineﬃ  cient for use in vivo.  Polycationic 
agents have toxicity and targeting problems,  electro-
poration causes high cell mortality and microinjection 
can only be applied to one cell at a time.  However, 
the use of non-viral synthetic vectors minimizes the 
risk of triggering an immune response in the treated 
individual because these vectors lack viral compo-
nents.  PTDs can also deliver plasmids.  Sakaguchi et 
al.  [37] designed a new system for transporting oli-
gonucleotides into cell nuclei.  The vehicle is com-
posed of glutathione-S-transferase,  7 arginine resi-
dues,  the DNA-binding domain of GAL4 and a 
nuclear localization signal,  which are linked with 
ﬂ exible glycine stretches.  The p53-responsive ele-
ment linked to the GAL4 upstream activating 
sequence was eﬃ  ciently transferred by the vehicle 
protein into the nuclei of primary cultures of neuro-
nal cells,  embryonic stem cells,  and various human 
normal cells.  The peptide sequence PKKKRKV has 
mostly been used as a nuclear localization signal 
(NLS),  but it has been suggested that this peptide 
also has cell-penetrating features,  and it has been 
shown to translocate proteins larger than 970 kDa 
into the nucleus [38].  The linking of the SV40 NLS 
peptide sequence via PNA to a reporter gene carry-
ing the vector,  transfecting cells and PEI,  resulted 
in an up to eightfold increase in the nuclear uptake of 
EGFP or lacZ-carrying plasmids,  compared with 
only PEI acting as the transfecting agent [31].
　　Transfection by PTD vectors might use the 
counter charge between negatively charged plasmid 
DNA and the positively charged peptide.  Hyndman et 
al.  [39] demonstrated that incorporation without 
covalent linkage of a TAT PTD peptide into gene 
delivery lipoplexes improved gene transfer. 
Furthermore,  sterilized R8 (arginine-8) peptides 
have been shown to transfect luciferase-containing 
plasmids into the nucleus with an eﬃ  ciency that is 
comparable to LipofectamineTM [40].  To avoid loss 
of translocation as a result of the PTD interacting 
with DNA,  the PTD can be designed as a branched 
complex to interact with DNA and mediate membrane 
translocation.  Eight-branched TAT has been used to 
transfect cells,  with results equivalent to standard 
LipofectamineTM strategies [41].  These systems can 
be a convenient and powerful tool for speciﬁ cally dis-
rupting the function of DNA-binding proteins.
　　Delivery of genome of bacterial phage and 
virus. An extreme case is the intracellular 
addressing of bacterial phages and viruses [5,  42, 
43].  Eguchi et al.  constructed recombinant lambda 
phage particles displaying TAT-PTD on their sur-
faces and carrying mammalian marker genes as part 
of their genomes [42].  When animal cells are brieﬂ y 
exposed to the TAT-phage,  signiﬁ cant expression of 
phage marker genes is induced with no harmful 
eﬀ ects to the cells.  Given the size of the phage 
genome,  the technology could therefore be used to 
introduce up to 20,000 bp of foreign coding DNA into 
cells.  Similarly,  incubating a combination of viral 
vectors and PTDs before viral infection can improve 
viral gene delivery.  The use of adenovirus and Antp-
PTD simultaneously signiﬁ cantly improved the eﬃ  -
ciency of the gene delivery of green ﬂ uorescent pro-
tein (GFP) and ｹ-Gal by adenovirus in vivo and in 
vitro [43].  Antp-PTD can promote viral uptake with-
out genetic coupling,  perhaps through the interaction 
of Antp-PTD with coat proteins.  A possible mecha-
nism is that the amphipathic peptide binds the virus 
or phage through its hydrophobic side and the lipids 
through its charged side.
　　These data may have signiﬁ cant implications for 
the future of other molecule delivery systems in vitro 
and in vivo.
Mechanisms of Protein Transduction
　　One structural cellular membrane component is 
required for PTD internalization.  It is shown that 
increasing concentrations of heparin could compete 
with TAT-PTD internalization [44].  Not surpris-
ingly given their highly basic charge,  TAT peptides 
bind to heparin [45ﾝ47].  This work led to the dis-
covery that cell-surface heparin sulfate proteoglycans 
appear to be key mediators of peptide internalization 
[48].  Consistent with this observation,  cells geneti-
cally impaired in the biosynthesis of fully sulfonated 
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heparin sulfate proteoglycans were selectively 
impaired for transduction by a TAT fusion protein 
[48],  poly-arginine,  and BETA2/NeuroD PTD 
(Noguchi et al. unpublished data).  In addition,  PTD 
uptake could be competitively inhibited by the selec-
tive degradation of the heparin sulfate sidechains 
using glycosaminoglycan lyases (Noguchi et al. unpub-
lished data).  The ubiquitous presence of heparin sul-
fate might explain the observation that PTDs and 
conjugated proteins are able to enter a wide variety 
of cells.  This interaction at the cell surface is likely 
to mediate the uptake of other arginine-rich PTDs. 
For example,  Antp-PTD has also been found to 
interact strongly with cellular membranes [49].
　　Early studies showed that the internalization of 
TAT-PTD,  Antp-PTD,  or polyR-PTD was not sig-
niﬁ cantly inhibited by incubation at 4 °C,  by deple-
tion of the cellular ATP pool,  or by inhibitors of 
endocytosis ; additionally,  internalization did not 
depend on a speciﬁ c primary sequence,  implying that 
receptor recognition was not necessary [18,  50,  51]. 
Therefore,  it had been commonly accepted that the 
internalization of PTD-containing proteins involves 
neither endocytosis nor speciﬁ c protein transporters. 
However,  some mechanistic studies suggest that both 
the import and nuclear localization of PTD-containing 
proteins occur only during ﬁ xation and not in living 
cells [52,  53].  Lundberg and Johansson showed that 
ﬁ xation with methanol induces an artiﬁ cial inﬂ ux of 
both VP22 protein from the Herpes Simplex virus and 
the positively charged histone H1 [52].  Additionally, 
both TAT-PTD and VP22-PTD were shown to medi-
ate cell binding but not translocation [53].  These 
data suggest that the protein transduction does not 
occur in living cells.  However,  a large number of 
studies have recently reported PTDs in living cells 
using both reporter proteins and/or functional pep-
tides/proteins.  Indeed,  protein transduction MUST 
work in living cells because many published studies 
have demonstrated PTD-mediated delivery of 
BIOLOGICALLY ACTIVE proteins/peptides.  The 
following three models have emerged to explain PTD 
uptake in recent reports.
　　One model is the perpendicular insertion of 
amphipathic peptides into the membrane,  with hydro-
phobic residues juxtaposing the lipids and the assem-
bled hydrophilic faces forming a channel through 
oligomerization.  This would allow eﬃ  cient passage 
of hydrophilic cargoes,  but would also be a threat to 
cell survival.  Several peptides can form pores at the 
cell surface and,  indeed,  induce cell death.  One 
example of this is provided by defensins [54],  a 
class of small peptides that form holes in microbial 
membranes and are produced by the invertebrate 
immune system and by some vertebrate cells.
　　A second model proposes that peptides bind to 
the polar heads of lipids in the membrane through 
electrostatic interaction,  resulting in transient for-
mation of inverted micelles that engulf the peptide 
and its cargo,  even at 4 °C.  The re-opening of the 
micelle inside the cell would then result in release of 
the PTD － cargo construct into the cytoplasm.  Some 
experiments suggest that Antp-PTD might use this 
pathway.  The addition of Antp-PTD to a ﬁ lm of 
brain lipids induces the formation of inverted 
micelles.  [55] A peptide of the same length,  charge 
and hydrophobicity in which a tryptophan has been 
changed into a phenylanine (W6F variant) still binds 
the lipids [56,  57] but is not internalized [58] and 
does not induce inverted micelle formation.  However, 
inverted micelle formation would limit cargo size and 
require the presence of hydrophobic amino acids, 
which are absent in TAT-PTD and poly-arginine-
PTDs ; thus,  such a mechanism is unlikely to be a 
common PTD delivery mechanism.
　　A third model is endocytosis followed by pas-
sage from the vesicle into the cytoplasm ; although 
this implies vesicle disruption,  the plasma membrane 
and cell viability are not aﬀ ected.  Some studies have 
shown that TAT-PTD,  polyR-PTD,  Antp-PTD,  and 
arginine-rich peptide SynB enter cells by endocytosis 
rather than by temperature- or energy-independent 
translocation [59,  60].  We observed,  for the ﬁ rst 
time,  protein transduction in real time.  TAT-PTD, 
11R-PTD,  and BETA2/NeuroD transcription fac-
tor,  which has an arginine- and lysine-rich PTD, 
penetrates into cells by macropinocytosis,  a type of 
endocytosis,  and is released from the endosome 
homogeneously into the cytoplasm and nuclei by ret-
rograde transport [2,  19].  Antp-PTD and PDX-1 
protein,  which has Antp-like PTD,  is also internal-
ized into cells by the same mechanism [2,  3]. 
Recently,  the role of endosomal acidiﬁ cation and ret-
rograde transport for the uptake of Antp-PTD, 
TAT-PTD,  and 9R-PTD was reported [61].  A num-
ber of well-characterized toxins reach the cytosol of 
7Protein Transduction TechnologyFebruary 2006
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eukaryotic cells after binding to the cell surface, 
undergoing endocytosis and retrograde transport to 
the Golgi apparatus and endoplasmic reticulum [62, 
63,  64].  The arginine-rich motif of 8ﾝ10 amino acids 
in the A subunits of these toxins,  reported to be 
transported by means of retrograde transport,  is 
similar to those of TAT-PTD,  Antp-PTD [61] and 
PDX-1-PTD.  PTDs,  even Antp-PTD,  transport by 
a similar mechanism to that of these protein toxins.
　　In conclusion,  the primary mechanism of protein 
transduction is an electrostatic interaction with the 
plasma membrane,  penetration into cells by macropi-
nocytosis,  and release to the cytoplasm and nuclei by 
retrograde transport.  However,  it is not possible to 
completely eliminate the possibility of partial uptake 
across the plasma membrane via other mechanisms.
Future Objectives
　　Protein transduction technology has some disad-
vantages.  One is that transduced proteins only have 
a limited active half-life,  so that their eﬀ ects are 
only transient.  Michiue et al.  showed that mutant 
proteins of p53 in which multiple lysine residues in 
the C-terminal were replaced by arginines were eﬀ ec-
tively delivered into glioma cells and were resistant 
to Mdm2-mediated ubiquitination [65].  The mutant 
proteins displayed higher transcription regulatory 
activity and induced powerful inhibition of glioma cell 
proliferation.  These ﬁ ndings suggest that ubiquitina-
tion-resistant proteins may become a more eﬀ ective 
strategy for protein transduction technology.
　　Another disadvantage is accumulation of PTDs 
or PTD-fused proteins in the endocytic compartment. 
The main mechanism of protein transduction is pene-
tration into cells by macropinocytosis and release to 
the cytoplasm and nuclei by retrograde transport. 
Although PTDs or PTD-fused proteins can be trans-
duced into cells by macropinocytosis,  such proteins 
are often entrapped inside macropinosomes in the 
cytoplasm.  Therefore,  high dose concentrations of 
PTDs or PTD-fused proteins are needed for the 
technology to function eﬀ ectively.  To overcome this 
problem,  the proteins were linked with the NH2-
terminal domain of inﬂ uenza virus hemagglutinin-2 
subunit (HA2),  which is a pH-dependent fusogenic 
peptide that induces the lysis of membranes at low 
pH levels [21,  66].  The pH-sensitive HA2 peptide 
markedly and speciﬁ cally enhanced macropinosome 
escape [66].  HA2- and polyarginine-fused p53 
induced p21(WAF1) transcriptional activity and 
inhibited the growth of cancer cells more eﬀ ectively 
than a polyarginine-fused p53 protein [21]. 
Moreover,  we developed methods of enhancing endo-
some escape using photo-sensitive PTD [6].  These 
techniques can enhance the eﬃ  ciency of the protein 
transduction system.
　　In some protein transduction experiments,  the 
activity of internalized proteins was not retained fol-
lowing insertion into the cell.  To resolve this issue, 
proteins and compounds could be coupled to PTDs 
via a linker designed to release the active proteins 
and drugs within cells.  Organ-speciﬁ c delivery involv-
ing PTDs also poses a complex challenge with 
respect to the utility of this technology as a clinical 
tool.  The technology cannot be applied to insoluble 
proteins due to diﬃ  culties associated with puriﬁ ca-
tion of these molecules.  Overcoming these obstacles 
will require advances involving reﬁ ned PTD 
sequences and improved application.
Physiological and Developmental Implications
　　PTDs are deﬁ ned by their ability to reach the 
cytoplasmic and/or nuclear compartments in live 
cells after internalization.  The initial discovery of 
PTDs originated from the unexpected observation 
that certain full-length proteins or protein domains 
can translocate across the plasma membrane.  This 
was ﬁ rst shown for the HIV TAT transactivator [67, 
68] and for the homeodomain of the Drosophila mela-
nogaster transcription factor Antennapedia [69],  and 
has since expanded to include ‘non-natural’ peptides 
that share this property.  In the case of homeodo-
main- and TAT-derived peptides,  and in contrast 
with many other PTDs,  uptake seems to reﬂ ect an in 
vivo biological process.  In support of this,  the trans-
locating activity of these peptides correlates with 
that of their parental full-length proteins [70], 
strongly suggesting that,  in some circumstances, 
these proteins may have paracrine activities as part 
of a physiological process,  in that they are released 
by one kind of cell and then internalized by other 
cells.  Accordingly,  the full-length proteins are also 
secreted,  probably by unconventional secretion path-
ways that do not involve a secretion signal sequence 
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[71,  72].  Recent reports of homeoproteins show 
that HOXB4 protein stimulates the non-oncogenic 
proliferation of CD34 haematopoietic stem cells [73], 
and that PDX-1 protein can transform duct cells into 
insulin producing cells [1ﾝ3].  Moreover,  we 
reported that BETA2/NeuroD protein,  one of the 
bHLH transcription factors,  can also be transduced 
into cells due to its own arginine- and lysine-rich 
sequence [19].  BETA2/NeuroD and PDX-1 pro-
teins are important in pancreatic development [74, 
75].  The pdx-1 gene has A-boxes,  and the PDX-1 
protein can positively autoregulate its expression 
[76] ; the BETA2/NeuroD gene also has E-boxes, 
and the BETA2/NeuroD protein can stimulate its 
own transcription [77].  The positive autoregulation 
of these proteins leads us to consider a potential 
paracrine role in neogenesis.  Once BETA2/NeuroD 
and PDX-1 proteins are transduced into progenitor 
cells,  endogenous BETA2/NeuroD and pdx-1 gene 
transcription are ampliﬁ ed by these proteins,  stimu-
late insulin transcription,  and may facilitate their 
diﬀ erentiation to insulin-producing cells.
　　Although the exact function of this intercellular 
transfer is not yet clear,  recent data on transcription 
factors,  in particular,  homeoproteins,  suggest that, 
after transfer,  the transcription factor can regulate 
transcription and translation in the recipient cell, 
thus acting as a ‘messenger protein’ [4,  78].  As 
homeoprotein expression is regionally speciﬁ ed,  it 
has been speculated that this corresponds to the pas-
sage of positional information between cells [4,  78].
Conclusions
　　The present protein transduction system has low 
toxicity and a high yield of delivery.  The use of this 
system opens up interesting therapeutic perspectives. 
The interest in protein translocation across mem-
branes is not limited to PTDs and their use as a tool 
with which to investigate cell biology,  or conversely 
to their biotechnological applications.  The intercellu-
lar transfer of endogenous transcription factors, 
such as TAT and homeoproteins,  seems to point to 
an original and important mode of signal transduc-
tion.  The physiological signiﬁ cance of these path-
ways requires further exploration.
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